articleThe Lancet OncologySep 9, 2013Closed access

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

DCDavid CunninghamILIstván LángEMEugenio MarcuelloVLVito LorussoJOJanja Ocvirk

Royal Marsden Hospital · National Institute of Oncology · +7 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

653
total citations
FWCI
31.03
Percentile
100%
References
30
Citations per year

Authors

11

Topics & keywords

Topics
Keywords
  • Capecitabine
  • Medicine
  • Bevacizumab
  • Internal medicine
  • Irinotecan
  • Colorectal cancer
  • Hazard ratio
  • Clinical endpoint
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding